Simvastatin in Aneurysmal Subarachnoidal Haemorrhage (STASH): a multicentre randomized controlled clinical phase III study - STASH

Cambridge University Hospitals NHS Foundation Trust0 个研究点目标入组 803 人开始时间: 2006年11月23日最近更新: 2022年1月24日

适应症

试验速览

暂无简介。

•1. Patients aged 18-65 years
•2. The admitting neurosurgeon has a high index of suspicion of a spontaneous aneurysmal subarachnoid haemorrhage (good clinical history with convincing CT findings).
•3. Any clinical grade accepted provided there is a reasonable prospect of survival.
•4. Delay to randomisation and initiation of trial medication, from the time of the presenting bleed, does not exceed 96 hrs.
•5. Independent prior to SAH.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. Unsalvageable patients: fixed dilated pupils after resuscitation, and/or a devastating scan, which precludes definitive therapy.
•2. Alreadey taking statin therapy.
•3. Those taking Warfarin-type drugs.
•4. Pregnancy.
•5. Known renal or hepatic impariment.
•6. Suspected or known additional disease process, which threatens life expectancy (e.g. malignancy).
•7. Known or strong suspicion of drug abuse, alcoholism or those who are unlikely to be amenable to 6 months follow up.

发起方